Apigenin promotes osteogenic differentiation of human mesenchymal stem cells through JNK and p38 MAPK pathways

Molecular and Cellular Biochemistry

Volumn 407, Issue 1-2, 2015, Pages 41-50

  Zhang, Xue ^a   Zhou, Chenhui ^a   Zha, Xuan ^a   Xu, Zhoumei ^a   Li, Li ^a   Liu, Yuyu ^a   Xu, Liangliang ^b   Cui, Liao ^a   Xu, Daohua ^a   Zhu, Baohua ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apigenin; JNK and p38 MAPK signaling pathway; Mesenchymal stem cell; Osteogenesis; Osteoporosis

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALKALINE PHOSPHATASE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APIGENIN; CALCIUM; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOPONTIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX2; RUNX2 PROTEIN, HUMAN;

ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL VIABILITY; CONCENTRATION RESPONSE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MTT ASSAY; OSTEOBLAST; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM;

MUS;

ALKALINE PHOSPHATASE; APIGENIN; CELL DIFFERENTIATION; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; OSTEOPONTIN;

EID: 84939263812     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2452-9     Document Type: Article

References (42)

1. Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747–783
2. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276–1287
3. Marie PJ, Kassem M (2011) Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol 165:1–10
4. Sandhu SK, Hampson G (2011) The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol 64:1042–1050
5. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147
6. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41–49
7. Wang X, Wang Y, Gou W, Lu Q, Peng J, Lu S (2013) Role of mesenchymal stem cells in bone regeneration and fracture repair: a review. Int Orthop 37:2491–2498
8. Cao L, Liu G, Gan Y, Fan Q, Yang F, Zhang X, Tang T, Dai K (2012) The use of autologous enriched bone marrow MSCs to enhance osteoporotic bone defect repair in long-term estrogen deficient goats. Biomaterials 33:5076–5084
9. Shekkeris AS, Jaiswal PK, Khan WS (2012) Clinical applications of mesenchymal stem cells in the treatment of fracture non-union and bone defects. Curr Stem Cell Res Ther 7:127–133
10. Guan M, Yao W, Liu R, Lam KS, Nolta J, Jia J, Panganiban B, Meng L, Zhou P, Shahnazari M, Ritchie RO, Lane NE (2012) Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 18:456–462
11. Dalle Carbonare L, Valenti MT, Zanatta M, Donatelli L, Lo Cascio V (2009) Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. Arthritis Rheumatol 60:3356–3365
12. Benisch P, Schilling T, Klein-Hitpass L, Frey SP, Seefried L, Raaijmakers N, Krug M, Regensburger M, Zeck S, Schinke T, Amling M, Ebert R, Jakob F (2012) The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One 7:e45142
13. Pino AM, Rosen CJ, Rodriguez JP (2012) In osteoporosis, differentiation of mesenchymal stem cells (MSCs) improves bone marrow adipogenesis. Biol Res 45:279–287
14. Jarry H, Spengler B, Porzel A, Schmidt J, Wuttke W, Christoffel V (2013) Evidence for estrogen receptor beta-selective activity of vitex agnus-castus and isolated flavones. Planta Med 69:945–947
15. Shukla S, Gupta S (2004) Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinogen 39:114–126
16. Fang J, Zhou Q, Liu LZ, Xia C, Hu X, Shi X, Jiang BH (2007) Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28:858–864
17. Hiremath SP, Badami S, Hunasagatta SK, Patil SB (2000) Antifertility and hormonal properties of flavones of Striga orobanchioides. Eur J Pharmacol 391:193–197
18. Shukla S, Gupta S (2007) Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 6:1102–1114
19. Rithidech KN, Tungjai M, Reungpatthanaphong P, Honikel L, Simon SR (2012) Attenuation of oxidative damage and inflammatory responses by apigenin given to mice after irradiation. Mutat Res 749:29–38
20. Bandyopadhyay S, Lion JM, Mentaverri R, Ricupero DA, Kamel S, Romero JR, Chattopadhyay N (2006) Attenuation of osteoclastogenesis and osteoclast function by apigenin. Biochem Pharmacol 72:184–197
21. Hougee S, Sanders A, Faber J, Graus YM, van den Berg WB, Garssen J, Smit HF, Hoijer MA (2005) Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem Pharmacol 69:241–248
22. Choi EM (2007) Apigenin increases osteoblastic differentiation and inhibits tumor necrosis factor-alpha-induced production of interleukin-6 and nitric oxide in osteoblastic MC3T3-E1 cells. Pharmazie 62:216–220
23. Jung WW (2014) Protective effect of apigenin against oxidative stress-induced damage in osteoblastic cells. Int J Mol Med 33:1327–1334
24. Park JA, Ha SK, Kang TH, Oh MS, Cho MH, Lee SY, Lee SY, Park JH, Kim SY (2008) Protective effect of apigenin on ovariectomy-induced bone loss in rats. Life Sci 82:1217–1223
25. Goto T, Hagiwara K, Shirai N, Yoshida K, Hagiwara H (2015) Apigenin inhibits osteoblastogenesis and osteoclastogenesis and prevents bone loss in ovariectomized mice. Cytotechnology 67:357–365
26. Liao Y, Shen W, Kong G, Lv H, Tao W, Bo P (2014) Apigenin induces the apoptosis and regulates MAPK signaling pathways in mouse macrophage ANA-1 cells. PLoS One 9:e92007
27. Ye Y, Wang H, Chu JH, Chou GX, Yu ZL (2011) Activation of p38 MAPK pathway contributes to the melanogenic property of apigenin in B16 cells. Exp Dermatol 20:755–757
28. Wang X, Goh CH, Li B (2007) p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix. Endocrinology 148:1629–1637
29. Greenblatt MB, Shim JH, Zou W, Sitara D, Schweitzer M, Hu D, Lotinun S, Sano Y, Baron R, Park JM, Arthur S, Xie M, Schneider MD, Zhai B, Gygi S, Davis R, Glimcher LH (2010) The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest 120:2457–2473
30. Kwon HS, Johnson TV, Tomarev SI (2013) Myocilin stimulates osteogenic differentiation of mesenchymal stem cells through mitogen-activated protein kinase signaling. J Biol Chem 288(23):16882–16894
31. Xu D, Xu L, Zhou C, Lee WY, Wu T, Cui L, Li G (2014) Salvianolic acid B promotes osteogenesis of human mesenchymal stem cells through activating ERK signaling pathway. Int J Biochem Cell Biol 51:1–9
32. Patel D, Shukla S, Gupta S (2007) Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol 30:233–245
33. Orimo H, Shimada T (2008) The role of tissue-nonspecific alkaline phosphatase in the phosphate-induced activation of alkaline phosphatase and mineralization in SaOS-2 human osteoblast-like cells. Mol Cell Biochem 315:51–60
34. Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA (2007) Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. Bone 41:462–473
35. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89:747–754
36. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B (2002) The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17–29
37. Gordeladze JO, Noel D, Bony C, Apparailly F, Louis-Plence P, Jorgensen C (2008) Transient down-regulation of cbfa1/Runx2 by RNA interference in murine C3H10T1/2 mesenchymal stromal cells delays in vitro and in vivo osteogenesis, but does not overtly affect chondrogenesis. Exp Cell Res 314:1495–1506
38. Tu Q, Valverde P, Chen J (2006) Osterix enhances proliferation and osteogenic potential of bone marrow stromal cells. Biochem Biophys Res Commun 341:1257–1265
39. Yao KL, Todescan R Jr, Sodek J (1994) Temporal changes in matrix protein synthesis and mRNA expression during mineralized tissue formation by adult rat bone marrow cells in culture. J Bone Miner Res 9:231–234
40. Liao QC, Xiao ZS, Qin YF, Zhou HH (2007) Genistein stimulates osteoblastic differentiation via p38 MAPK–Cbfa1 pathway in bone marrow culture. Acta Pharmacol Sin 28:1597–1602
41. Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G, Caverzasio J (2003) Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 18:2060–2068
42. Cuenda A, Rousseau S (2007) p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773:1358–1375